ZINNAT Suspension (available as
cefuroxime axetil granules for oral
suspension, 125 mg/5ml, 70ml) will
be listed on the Pharmaceutical
Benefits Scheme as an unrestricted
General Benefit Item from 01
August 2012.
The listing follows a
recommendation by the
PBAC that Zinnat Suspension be
placed on the PBS on the basis of a
clinical need in the paediatric
population and acceptable cost
effectiveness.
Zinnat Suspension is indicated for
the treatment of mild to
moderately severe tonsillitis,
pharyngitis and acute bacterial
otitis media in paediatric patients 3
months to 12 years.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 12
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.